Indeed, in NAFLD patients, LPS-induced activation of liver MFs is associated with inflammation and fibrosis, and both TLR4 knockout (KO) and clodronate-mediated hepatic MF depletion attenuate experimental NASH [132,133]. This evidence concerns the gene TLR4 and metabolic dysfunction-associated steatotic liver disease.